CGRP vs PEG-MGF

Binds CLR/RAMP1 receptor complex. Causes vasodilation via cAMP/PKA/nitric oxide pathway. Modulates nociceptive signaling in the trigeminal system. Promotes bone healing and has anti-inflammatory effects in peripheral tissues.

CGRP (calcitonin gene-related peptide) is a 37-amino-acid endogenous neuropeptide produced by alternative splicing of the calcitonin gene, expressed predominantly in sensory neurons of the trigeminal system and peripheral vasculature, where it functions as a potent vasodilator and pain neuromodulator central to migraine pathophysiology. CGRP activates its receptor complex (CLR/RAMP1) to mediate vasodilation and nociceptive signal amplification; during migraine attacks, trigeminal activation releases CGRP at elevated plasma concentrations, and blockade of this pathway has been established as the primary validated pharmacological target for modern preventive migraine therapy. Phase 3 randomized controlled trials published in the New England Journal of Medicine and the Lancet — including the STRIVE trial (Goadsby et al. 2017) and a Phase 3b study in treatment-refractory patients — demonstrated that anti-CGRP monoclonal antibodies significantly reduced monthly migraine days versus placebo, validating the pathway and supporting FDA approval of erenumab, fremanezumab, and galcanezumab. CGRP itself is an endogenous neuropeptide and is not a therapeutic agent that is compounded or administered by providers; the FDA-approved interventions are monoclonal antibody and small-molecule receptor antagonists available by prescription, and exogenous CGRP peptide is exclusively a research tool compound used in vasodilatory and pain signaling pharmacology studies.

Pegylated form of MGF; activates muscle stem cells (satellite cells) to repair and regenerate muscle tissue after damage

PEG-MGF (pegylated mechano growth factor) is a synthetic derivative of mechano growth factor (MGF, IGF-1Ec), in which the bioactive C-terminal E-peptide domain of the IGF-1 gene splice variant is chemically conjugated with polyethylene glycol (PEG) to improve aqueous stability and extend its proposed in vivo half-life relative to the rapidly degraded unmodified peptide. PEGylation is intended to preserve the proposed satellite cell-activating and tissue repair-promoting actions of the native MGF E-peptide over a longer post-administration window, with the pharmacological rationale extrapolated from preclinical and in vitro research on the parent MGF compound. No indexed peer-reviewed literature has been identified for PEG-MGF as a distinct chemical entity under its common name or under pegylated IGF-1 splice variant terminology in the biomedical literature, and the compound does not appear in PubMed with characterized pharmacokinetic or pharmacodynamic properties. PEG-MGF has no regulatory approval in any jurisdiction and no published human pharmacokinetic, safety, or efficacy data; it is sold as a research chemical by vendors without an evidence base establishing its biological activity as a defined and characterized therapeutic agent.